A Single Methamphetamine Administration Rapidly Decreases Vesicular Dopamine Uptake

  1. Jeffrey M. Brown,
  2. Evan L. Riddle,
  3. Verónica Sandoval,
  4. Raul K. Weston,
  5. Jarom E. Hanson,
  6. Michael J. Crosby,
  7. Yvette V. Ugarte,
  8. James W. Gibb,
  9. Glen R. Hanson and
  10. Annette E. Fleckenstein
  1. Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah
  1. Annette E. Fleckenstein, Ph.D., University of Utah, Department of Pharmacology and Toxicology, 30 South 2000 East, Room 201, Salt Lake City, UT 84112. E-mail:fleckenstein{at}hsc.utah.edu

Abstract

Recent studies demonstrated that vesicular dopamine (DA) uptake can be rapidly altered in synaptic vesicles purified from the striata of stimulant-treated rats. Specifically, a single administration of the plasmalemmal DA transporter inhibitor, cocaine, or the DA D2 agonist, quinpirole, increases vesicular DA uptake in vesicles purified from the striata of treated rats. These effects of cocaine are prevented by pretreatment with a D2, but not D1, DA receptor antagonist. The purpose of the present study was to characterize the effect of a mechanistically different psychostimulant, methamphetamine (METH), on vesicular DA uptake. Results demonstrated that a single administration of this DA-releasing agent rapidly and reversibly decreased vesicular DA uptake. The METH-related decrease in vesicular DA uptake was attenuated by pretreatment with the D2 antagonist, eticlopride, but not the D1 antagonist, SCH23390 (R-[+]-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine). Core body temperature did not contribute to the effects of METH on vesicular DA uptake. Neither quinpirole nor cocaine increased vesicular DA uptake when rats were concurrently treated with METH. These studies provide further evidence that psychostimulants rapidly and differentially modify vesicular DA uptake. In addition, these studies demonstrate a complex role for D2 DA receptors in altering vesicular DA transport.

Footnotes

  • This research was supported by National Institutes of Health Grants DA04222, DA00869, DA11389, and DA013367.

  • Abbreviations:
    DA
    dopamine
    VMAT-2
    vesicular monoamine transporter-2
    DHTBZ
    dihydrotetrabenazine
    GBR-12935
    1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine
    METH
    methamphetamine
    SCH-23390
    R-[+]-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
    • Received December 11, 2001.
    • Accepted April 16, 2002.
« Previous | Next Article »Table of Contents